Compare Becton Dickinson and Co (BDX) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Teladoc Health Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Teladoc Health Inc trades at $6.83 (market cap $1.29B). The key difference: Becton Dickinson and Co is far larger — about 37.9× Teladoc Health Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| BDX | TDOC | |
|---|---|---|
Market Cap | $48.93B | $1.29B |
Sector | Health | Health |
52-Week High | $185.39 | $9.72 |
52-Week Low | $138.62 | $4.47 |
Enterprise Value | $65.03B | $1.55B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
TDOC trades at $7.13, up 6.74% in the last session, but remains under pressure after a 28% drop in August 2026 due to a revenue miss and lowered guidance. The stock shows oversold technical signals with RSI near 24, while fundamentals reveal a net loss margin of -7.13% despite a gross margin of 68.97%. Recent news highlights multiple law firm investigations into securities claims, adding to investor uncertainty.
The outlook is cautious; analyst consensus is a hold with a $8.88 price target, but risks include ongoing losses, competitive pressures, and legal scrutiny. Upside depends on execution in integrated care, but near-term volatility is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
